Zobrazeno 1 - 10
of 2 615
pro vyhledávání: '"Non-alcoholic fatty liver Disease(NAFLD)"'
Publikováno v:
Clinical Diabetes and Endocrinology, Vol 10, Iss 1, Pp 1-19 (2024)
Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern and the risk of its development is connected with the increasing prevalence of metabolic syndrome (MetS) which occurs as a result of some
Externí odkaz:
https://doaj.org/article/a7550d63464f41babd1ee57f94d7fdb1
Autor:
Jingwen Zhang, Yan Wang, Sunkui Ke, Tianyu Xie, Lijun Liu, Xiaoyu Fu, Chenhao Wang, Xiao Huang
Publikováno v:
BMC Psychiatry, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The Weight-Adjusted Waist Index (WWI) is a novel indicator of obesity that accurately reflects body composition. However, the association between WWI and depression in patients with non-alcoholic fatty liver disease (NAFLD) remain
Externí odkaz:
https://doaj.org/article/028797452cdb47e0bba5f2fb083a4ef9
Publikováno v:
Shanghai Jiaotong Daxue xuebao. Yixue ban, Vol 44, Iss 10, Pp 1299-1306 (2024)
The endocannabinoid system (ECS) consists of a variety of long-chain unsaturated fatty acid analogs, mainly anandamide (AEA) and 2-arachidoniyl glycerol (2-AG), along with their specific binding G protein-coupled receptors, cannabinoid receptor 1 (CB
Externí odkaz:
https://doaj.org/article/81df7522de1247d7a202b8e68d859074
Autor:
Xue Wang, Jinlong You, Jing Tang, Xiuqian Li, Rui Wang, Yuanyuan Li, Yana Bai, Minzhen Wang, Shan Zheng
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Backgrounds This investigation seeks to explore the correlation between nonalcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVDs), and to to provide evidence for the prevention and treatment of CVDs. Methods This study util
Externí odkaz:
https://doaj.org/article/cc630909ab5b4919a9bc2e33b5b994b7
Autor:
Kanica Kaushal
Publikováno v:
Journal of Family Medicine and Primary Care, Vol 13, Iss 9, Pp 3536-3539 (2024)
Individuals who have non-alcoholic fatty liver disease (NAFLD) are at high risk of metabolic comorbidities and can put a significant strain on healthcare systems. If not managed in a timely manner, NAFLD can lead to sustained healthcare costs, econom
Externí odkaz:
https://doaj.org/article/ab61cde2ea784a5f8cfb93632ae42c47
Autor:
Jihan Fadhilah, Hainun Zariyah, Adriyan Pramono, Hery Djagat Purnomo, Ahmad Syauqy, Diana Nur Afifah, Farhan Syafiq Fadhillah, Rachmania Anggita Purwanti
Publikováno v:
Clinical Nutrition Open Science, Vol 56, Iss , Pp 128-151 (2024)
Summary: This systematic review and meta-analysis examine the impact of synbiotics on non-alcoholic fatty liver disease (NAFLD) by evaluating changes in lipid, glucose, and inflammatory profiles. A search across PubMed/Medline, Cochrane Library, Scop
Externí odkaz:
https://doaj.org/article/7427ca3ac8db426bb3a74a4370abdf64
Autor:
Marilena Anastasaki, Sophia Papadakis, Irini N. Gergianaki, Loucas Papastamatiou, Eftychios Aligizakis, Nikoleta Grillaki, Eleni Boutzoukaki, Nektarios Sivaropoulos, Foteini Anastasiou, Juan Mendive, Carlos de Juan-Asenjo, Rosario Hernández-Ibáñez, Alba Martínez-Escudé, Montserrat Garcia-Retortillo, Ger Koek, Leen Heyens, Jean Muris, Christos D. Lionis
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), emerges as major cause of morbidity and mortality globally, with chronic patients facing increased risk. Guidelines on MASLD management in primary care (PC) a
Externí odkaz:
https://doaj.org/article/a224564afeec41b98724528e4765cd41
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver condition closely associated with metabolic syndrome, with its incidence rate continuously rising globally. Recent studies have shown that the development of NAFLD is associated with insuli
Externí odkaz:
https://doaj.org/article/7482bfc2f5a143bc98cbabb6994c52e5
Autor:
Syed Hussain Abbas, Carlo D. L. Ceresa, Leanne Hodson, David Nasralla, Christopher J. E. Watson, Hynek Mergental, Constantin Coussios, Fotini Kaloyirou, Kerrie Brusby, Ana Mora, Helen Thomas, Daphne Kounali, Katie Keen, Joerg-Matthias Pollok, Rohit Gaurav, Satheesh Iype, Wayel Jassem, M. Thamara PR Perera, Abdul Rahman Hakeem, Simon Knight, Peter J. Friend
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-37 (2024)
Abstract Background Liver disease is the third leading cause of premature death in the UK. Transplantation is the only successful treatment for end-stage liver disease but is limited by a shortage of suitable donor organs. As a result, up to 20% of p
Externí odkaz:
https://doaj.org/article/98ef5b3b7cbc474299044fd34c976031
Autor:
Jin Imai, Shinji Takashimizu, Nana Suzuki, Kana Ohshinden, Kana Sawamoto, Yusuke Mishima, Kota Tsuruya, Yoshitaka Arase, Mitsuhiko Yamano, Noriaki Kishimoto, Chizumi Yamada, Nagamu Inoue, Kengo Moriyama, Akiyasu Baba, Hidekazu Suzuki, Tatehiro Kagawa, Yasuhiro Nishizaki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract A novel concept of Metabolic Associated Fatty Liver Disease (MAFLD) was proposed, incorporating metabolic abnormalities such as obesity and diabetes, which are risk factors that affect the prognosis. Non-Alcoholic Fatty Liver Disease (NAFLD)
Externí odkaz:
https://doaj.org/article/754dd757f5864b4b8113368be53e7250